Pioglitazone may reduce cardiovascular events in high risk patients with prediabetes

Pioglitazone was incorrectly described as a PPAR-gamma inhibitor in this News story (BMJ 2016;352:i1029, doi:10.1136/bmj.i1029) when it is an agonist. The first sentence of the third paragraph should read that pioglitazone “improves insulin sensitivity by stimulating [not inhibiting] peroxisome proliferator activated receptor gamma.”